ApoB/apoA-I ratio is better than LDL-C in detecting cardiovascular risk

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 21, Issue 6, 2011, Pages 406-411

  Carnevale Schianca, G P ^a   Pedrazzoli, R ^a   Onolfo, S ^a   Colli, E ^a   Cornetti, E ^a   Bergamasco, L ^a   Fra, G P ^a   Bartoli, E ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Apob Apoa I ratio; Cardiovascular risk; Insulin resistance; LDL C; Metabolic syndrome

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PATHOLOGY; RISK FACTOR;

ADULT; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; COHORT STUDIES; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS;

EID: 79955953580     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2009.11.002     Document Type: Article

References (29)

1. Anderson K.M., Castelli W.P., Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. J Am Med Assoc 1987, 257:2176-2180.
2. Genest J., McNamara J.R., Ordovas J.M., Silberman S.R., Anderson K.M., Wilson P.W., et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992, 19:792-802.
3. Walldius G., Jungner I., Holme I., Aastveit A.H., Kolar W., Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001, 358:2026-2033.
4. Walldius G., Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 2004, 255:188-205.
5. Yusuf S., Hawken S., Öunpuu S., Dans T., Avezum A., Fernando L., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
6. Meisenger C., Loewel H., Mraz W., Koenig W. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. Eur Heart J 2005, 26:271-278.
7. Sniderman A.D., Furberg C.D., Keech A., Roeter s van Lennep J.E., Frohlic J., Junger I., et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003, 361:777-780.
8. Walldius G., Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy- a review of the evidence. J Intern Med 2006, 259:493-519.
9. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22. Heart Protection Study Collaborative Group.
10. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., et al. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.
11. Expert Panel on Detection Evaluation, and treatment of high blood cholesterol in adults, third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. (Adult treatment Panel III) final report. Circulation 2002, 106:3143-3421.
12. Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110(2):227-239.
13. Sacks F.M., Tonkin A.M., Shepherd J., Braunwald E., Cobbe S., Morton Hawkins F., et al. Effect of Pravastatin on coronary disease in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 2000, 102:1893-1900.
14. Pyörälä K., Ballanttyne C.M., Gumbiner B., Lee M.W., Shah A., Davies M.J., et al. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Survival Study (4S). Diabetes Care 2004, 27:1735-1740.
15. Grundy S.M., Hansen B., Smith S.C., Cleeman J.I., Khan R.A. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association on scientific issues related to management. Circulation 2004, 4:551-556. for Conference Participants.
16. Expert Committee on the diagnosis and classification of diabetes mellitus Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003, 26:S5-20.
17. Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modelling. Diabetes Care 2004, 27:1487-1495.
18. Levenson J.W., Skerret P.J., Gaziano J.M. Reducing the global burden of cardiovascular disease: the role of risk factors. Prev Cardiol 2002, 5:88-89.
19. Simon A., Chironi G., Gariepy J., Del Pino M., Levenson J. Differences between markers of atherogenic lipoproteins in predicting high cardiovascular risk and subclinical atherogenesis in asymptomatic men. Atherosclerosis 2005, 179:339-344.
20. Hu G., Qiao Q., Tuomilehto J., Balkau B., Borch-Johnsen K., Pyörälä K. DECODE Study, Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004, 10:1066-1076.
21. Marcovina S., Packard C.J. Measurements and meaning of apolipoprotein AI and apolipoprotein B plasma levels. J Intern Med 2006, 259:437-446.
22. Sniderman A.D. Apolipoprotein B versus no-high density lipoprotein cholesterol. And the winner is .... Circulation 2005, 112:336-337.
23. Barter P. The role of HDL-cholesterol in preventing atherosclerotic disease. Eur Heart J Suppl 2005, 7:F4-8.
24. Ingelsson E., Schaefer E.J., Contois J.H., McNamara J.R., Sullivan L., Keyes M.J., et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. J Am Med Assoc 2007, 298:776-785.
25. Shai I., Rimm E.B., Hankinson S.E., Curhan E., Manson J.E., Rifai N., et al. Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women. Potential implications for clinical guidelines. Circulation 2004, 110:2824-2830.
26. Scharnagl H., Nauck M., Wieland H., März W. The Friedewald formula underestimates LDL cholesterol at low concentrations. Clin Chem Lab Med 2001, 39:426-431.
27. Sniderman A.D., Blank D., Zakarian R., Bergeron J., Frohlich J. Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula. Clin Biochem 2003, 36:499-504.
28. Steinmetz J., Caces E., Couderc R., Beucler I., Legrand A., Henney J. Reference values of apolipoproteins AI and B. Contribution of International standardization. Ann Biol Clin 1997, 55:451-454.
29. Denke M.A. Weighing in before the fight. Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol versus apolipoprotein B as the best predictor for coronary heart disease and the best measure of therapy. Circulation 2005, 112:3368-3370.